Atle Fund Management AB decreased its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 42.2% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,806 shares of the medical research company’s stock after selling 10,088 shares during the period. Amgen makes up about 1.5% of Atle Fund Management AB’s holdings, making the stock its 26th biggest holding. Atle Fund Management AB’s holdings in Amgen were worth $3,896,000 at the end of the most recent ...

Core Insights - The Chief Scientific Officer of Scholar Rock Holding Corp, Mo Qatanani, sold 14,898 shares on January 22, 2026, for approximately $695,937, but this should not concern investors as it was part of a pre-scheduled trading plan [1][4]. Transaction Summary - The shares sold were part of a Rule 10b5-1 trading plan, indicating that the sale was pre-arranged and not a spontaneous decision [4]. - After the transaction, Qatanani retains direct ownership of 85,660 shares, which represents 21% of total holdings [5]. Company Overview - Scholar Rock Holding Corporation is a clinical-stage biotechnology company focused on developing therapies for severe diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and anemia [3]. - The company's current market capitalization is $4.52 billion, with a net income of -$353.43 million [2]. Future Plans - Scholar Rock plans to launch its key product candidate, apitegromab, in the U.S. and European markets, pending regulatory approvals [5]. - Apitegromab is positioned as the world's first and only muscle-targeted treatment for spinal muscular atrophy (SMA), a severe genetic neuromuscular disease [6].

Company Overview - Protagonist Therapeutics is a clinical-stage biotechnology company focused on addressing unmet medical needs in hematology and immunology, particularly for patients with rare blood disorders and inflammatory diseases [5] - The company has a market capitalization of $5.11 billion, with a revenue of $209.22 million and a net income of $45.91 million for the trailing twelve months (TTM) [4] - Protagonist's stock experienced a significant price change of 120.48% over the past year, calculated using January 31, 2026, as the reference date [4] Recent Transaction - Arturo Molina, Chief Medical Officer of Protagonist Therapeutics, sold 9,514 shares on January 20, 2026, for approximately $784,700, marking the largest direct open-market sale by him to date [1][6] - Post-transaction, Molina retains 97,266 shares valued at approximately $8.11 million [2] Market Sentiment - The majority of Wall Street analysts rate Protagonist Therapeutics' stock as a "strong buy," indicating positive sentiment towards the company's growth potential [6] - The company is projected to experience significant growth within the next 12-24 months, supported by partnerships with large firms like Johnson & Johnson [7][8] - Protagonist's stock soared approximately 123% in 2025, reflecting strong institutional investor support [8]

Core Insights - A Co-CEO of Amylyx Pharmaceuticals executed significant insider selling, but the sale was primarily to cover option costs and tax obligations, not discretionary [6][7] - The company has shown strong stock performance, with a 313% increase over the past year, recovering from previous losses [4][7] Transaction Summary - Joshua B Cohen sold 138,167 shares for approximately $1.9 million, following the exercise of 200,000 stock options [1][2] - Post-transaction, Cohen holds 3,379,465 shares, representing a 4.07% insider ownership [2][7] Company Overview - Amylyx Pharmaceuticals focuses on developing therapeutics for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) [5] - The company is advancing its flagship therapy, AMX0035 (RELYVRIO), which has shown effectiveness in slowing ALS progression [8] Financial Performance - The company's market capitalization is $1.57 billion, with a net income of -$149.28 million [4] - The stock price as of January 31, 2026, was $14.29, reflecting a significant recovery and growth [4] Investigations - Amylyx is currently under investigation for alleged breaches of fiduciary duties by its directors and officers, which may be a concern for investors [9]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on March 16, 2026 [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][7]. - The lead plaintiff must file a motion with the Court by March 16, 2026, to represent other class members in the litigation [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its success in this area [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is under development for treating social anxiety disorder [5]. - Defendants reportedly made overly positive statements about the drug's trial success while concealing adverse facts about the Phase 3 PALISADE-3 trial [6].

Core Insights - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has shown steady revenue growth, with a 3% increase in fourth-quarter sales compared to the previous year, driven by double-digit growth in three key products [2][3] Sales Performance - Global net sales of DUPIXENT increased by 32%, while LIBTAYO sales rose by 13% on a constant-currency basis [3] - In the U.S., EYLEA HD sales surged by 66%, indicating strong momentum in the domestic market [3] Product Highlights - DUPIXENT is described as a core pillar of Regeneron's business, currently used by over 1.4 million patients worldwide, with further growth anticipated [4] - LIBTAYO has shown progress, particularly in adjuvant CSCC and gaining market share in advanced non-small cell lung cancer, becoming the second most prescribed immunotherapy in the first-line setting in the U.S. [4] Future Outlook - The company has a busy regulatory and development agenda, expecting at least four FDA approvals, including three new molecular entities and the EYLEA HD prefilled syringe [5] - Plans include launching 18 additional Phase III studies over the coming years, with an estimated total enrollment of about 35,000 patients, aimed at supporting the next wave of potential blockbuster products [5]

In this article, we will discuss the 10 Best Nancy Pelosi Stocks to Buy in 2026.Nancy Pelosi is one of the most closely tracked members of Congress owing to her impressive record on Wall Street. Despite announcing plans to retire from Congress, her term runs until January 2027, giving investors time to access her investment portfolio.Over the past decade, Pelosi’s portfolio has generated an estimated cumulative return of 838%, beating the S&P 500’s 256%. In 2024, her portfolio rose 70.9%, dwarfing the S&P 5 ...

Core Viewpoint - Mirum Pharmaceuticals is showing strong performance and growth potential, with shares more than doubling over the past year, but it is not yet consistently profitable [1][2]. Financial Performance - For the first nine months of 2025, Mirum generated $372.4 million in revenue, reflecting a year-over-year increase of 56.8% [3]. - The company reported a loss per share of $0.35 for this period, an improvement from a loss of $1.36 per share in the same period last year [3]. - In Q3 2025, Mirum achieved a net profit of $2.9 million, a significant turnaround from a net loss of $14.2 million in Q3 2024 [4]. Revenue Projections - Mirum expects to achieve $520 million in net product sales for the full 2025 fiscal year, indicating at least a 54.4% growth compared to 2024 [6]. - For 2026, the company is guiding for net sales between $630 million to $650 million, representing a midpoint growth of 23.1% compared to 2025 [6]. Strategic Acquisitions - The company recently acquired Bluejay Therapeutics for $620 million, which may negatively impact short-term profitability due to acquisition costs but is expected to enhance revenue and earnings in the long run [7]. Future Outlook - Mirum has key clinical catalysts that could positively impact its stock price and drive sales growth [8]. - Despite recent strong performance, there are concerns about limited upside potential and the timeline for achieving consistent profitability [8][9].

Core Insights - Regeneron Pharmaceuticals, Inc. reported Q4 2025 results with revenue of $3.9 billion, a 3.0% increase year over year, exceeding consensus expectations by approximately 3% [1] - Adjusted EPS for the quarter reached $11.44, which is 7% above street expectations, indicating strong profitability [1] - The company's performance is driven by four blockbuster medicines and a promising late-stage clinical portfolio, with significant label expansions and new solutions for EYLEA HD [1] Financial Performance - Q4 revenue was $3.9 billion, reflecting a 3.0% year-over-year growth [1] - Adjusted EPS for Q4 was $11.44, exceeding expectations by 7% [1] - BofA Securities projected Q4 collaboration revenues from Sanofi at $1.6 billion, a 32% increase year over year, while Bayer collaboration revenues were estimated at $361 million, down 4% year over year [3] Product Developments - EYLEA HD received label expansions, enhancing its commercial potential [1] - Dupixent has new approvals in Japan and Europe, with over 1.4 million active patients globally, making it the most widely used innovative branded antibody medicine [1] - Libtayo secured additional approvals and remains a leading immunotherapy for non-melanoma skin cancers [1] Analyst Ratings and Projections - BofA Securities maintained a Buy rating with a price target of $860, incorporating the impact of R&D estimates and other disclosures [2] - Evercore ISI raised the price target to $875 from $750, reiterating an Outperform rating, emphasizing Dupixent's growth and Eylea HD's competitive prospects [4] - For 2026, BofA estimated U.S. Eylea franchise revenues at $4.43 billion, higher than previous forecasts and consensus [3]

Core Insights - BeOne Medicines AG (NASDAQ:ONC) is highlighted as a promising healthcare stock for 2026, showcasing significant advancements in its pipeline development [1] Pipeline Development - The company’s BRUKINSA, a tyrosine kinase inhibitor, has demonstrated a 74% six-year progression-free survival rate in treatment-naïve chronic lymphocytic leukemia (CLL), significantly outperforming the 32% rate of bendamustine plus rituximab [2] - Sonrotoclax, a BCL2 inhibitor, has received regulatory approval with an impressive overall response rate of 86% in heavily pretreated CLL patients [2] - BeOne Medicines is advancing 15 new molecular entities into clinical trials and plans to introduce an additional 8 to 10 candidates [2] Market Performance and Projections - Citizens has reiterated a Market Perform rating for BeOne Medicines with a price target of $396, citing strong efficacy data from a phase 3 trial in gastric cancer patients [3] - The anticipated approval of sonrotoclax is expected to lead to further global approvals, while Brukinsa is projected to generate $3.8 billion in revenue by 2025 [3] Company Overview - BeOne Medicines AG is a biotechnology firm focused on the discovery, development, and commercialization of innovative and affordable oncology treatments, known for products like Brukinsa and Tevimbra [4]